Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

27.86
+0.10400.37%
Volume:1.11M
Turnover:31.04M
Market Cap:19.94B
PE:-23.75
High:28.14
Open:27.60
Low:27.55
Close:27.76
52wk High:28.14
52wk Low:8.73
Shares:715.70M
Float Shares:467.00M
Volume Ratio:1.29
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1734
EPS(LYR):-0.2371
ROE:-19.14%
ROA:-14.47%
PB:4.67
PE(LYR):-117.53

Loading ...

Priovant's Brepocitinib Shows Skin Disease Improvement in Phase 2 Study; Pulmovant Completes Lung Disease Trial Enrollment

MT Newswires Live
·
Feb 06

Shares of Roivant up 15.8% Premarket After Experimental Drug Shows Benefit in Rare Skin Disease, Q3 Results

THOMSON REUTERS
·
Feb 06

Roivant Sciences posts nine-month revenue of USD 5.74 million, down 73 percent

Reuters
·
Feb 06

S&P 500 Futures Climb In Premarket Trading; Doximity, Stellantis Lag

Dow Jones
·
Feb 06

BUZZ-Roivant shares rise as experimental drug shows benefit in rare skin disease

Reuters
·
Feb 06

Roivant swings to Q3 loss as revenue drops

Reuters
·
Feb 06

Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q3 Net Loss $0.38 a Share, vs. FactSet Est of $0.30 Loss

MT Newswires Live
·
Feb 06

Stock Track | Roivant Sciences Soars 9.93% in Pre-market on Positive Phase 2 Results for Brepocitinib

Stock Track
·
Feb 06

Immunovant Q3 net loss smaller than expected

Reuters
·
Feb 06

Roivant Sciences Q3 Adj. EPS $(0.24) Beats $(0.32) Estimate, Sales $1.999M

Benzinga
·
Feb 06

BRIEF-Roivant Sciences Q3 Revenue USD 1.999 Million

Reuters
·
Feb 06

Priovant Therapeutics kündigt positive Phase-2-Studie mit Brepocitinib bei kutaner Sarkoidose an

Reuters
·
Feb 06

Roivant Sciences Q3 Operating Expenses USD 341.152 Million

THOMSON REUTERS
·
Feb 06

Roivant Sciences Ltd - Brepocitinib 45 Mg Shows Significant Improvement in Cutaneous Sarcoidosis

THOMSON REUTERS
·
Feb 06

Roivant Sciences Ltd: Jury Trial in the U.S. Moderna Case Scheduled for March 2026

THOMSON REUTERS
·
Feb 06

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (Cs) and Reports Financial Results for the Third Quarter Ended December 31, 2025

THOMSON REUTERS
·
Feb 06

Roivant Sciences Ltd - Topline Results Expected in Second Half of 2026

THOMSON REUTERS
·
Feb 06

Pulmovant Announces Completion of Enrollment in the Phase 2 Phocus Study of Mosliciguat in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (Ph-Ild)

THOMSON REUTERS
·
Feb 06

Roivant Sciences Ltd - Brepocitinib Well Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
Feb 06

Priovant: Plans to Progress Cs to a Pivotal Program With a Phase 3 Study Starting in Calendar Year 2026 Following Engagement With FDA

THOMSON REUTERS
·
Feb 06